#4D6D88_Small Cover_March-April 2024 DRA Journal

In this exclusive Show Preview Issue, we present the IDEM Singapore 2024 Q&A Forum featuring key opinion leaders; their clinical insights covering orthodontics and dental implantology; plus a sneak peek at the products and technologies set to take center stage at the event. 

>> FlipBook Version (Available in English)

>> Mobile-Friendly Version (Available in Multiple Languages)

Click here to access Asia's first Open-Access, Multi-Language Dental Publication

Sublingual Buprenorphine/Naloxone associated with more adverse dental outcomes

Canadian researchers are warning about a higher risk for adverse dental outcomes associated with sublingual buprenorphine/naloxone compared with transdermal buprenorphine or oral naltrexone.

According to a research letter published in current of the Journal of the American Medical Association, researchers from the University of British Columbia in Vancouver, Canada, used the PharMetrics database to examine the association between sublingual buprenorphine/naloxone and dental adverse events.

Participants in the new study included: 21,404 new users of sublingual buprenorphine/naloxone; 5,385 users of transdermal buprenorphine; and 6,616 users of oral naltrexone.

Click to Visit website of India's Leading Manufacturer of World Class Dental Materials, Exported to 90+ Countries.

Comparing “dental adverse events”

The scientists found varying incidence levels of “dental adverse event” between the different user groups: 21.6 per 1,000 person-years with sublingual buprenorphine/naloxone; 12.2 per 1,000 person-years with transdermal buprenorphine; and 10.9 per 1,000 person-years with oral naltrexone. The risk for dental adverse events was higher for sublingual buprenorphine/naloxone versus both transdermal buprenorphine and oral naltrexone.

In addition, the incidence of dental caries or tooth loss was 8.2 per 1,000 person-years with sublingual buprenorphine/naloxone; 3.5 per 1,000 person-years with transdermal buprenorphine; and 3.8 per 1,000 person-years with oral naltrexone.

Higher risk for dental caries/ tooth loss

Similarly, the scientists observed a higher risk for dental caries or tooth loss for sublingual buprenorphine/naloxone versus both transdermal buprenorphine and oral naltrexone.

“Clinicians might consider drugs other than sublingual buprenorphine/naloxone in patients with previous dental problems,” the authors wrote. “These patients might also benefit from regular oral health examinations by their dentist.”

Click here for the article: Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.

Note: Access to full text may require subscription or payment.

The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.

Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.

The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.

Leave a Reply

Your email address will not be published. Required fields are marked *